-Wall Street Journal
Why Are Pliant Therapeutics Shares Rallying Today?
Pliant Therapeutics Inc’s (NASDAQ:PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and…
Related Posts
Piper Sandler Upgrades Columbia Banking System to Overweight, Announces $32 Price Target
Piper Sandler analyst Matthew Clark upgrades Columbia Banking System (NASDAQ:COLB) from Neutral to Overweight and announces $32 price target.
Eldorado Gold Q3 Adj. EPS $(0.04) Misses $0.08 Estimate, Sales $217.70M Miss $228.29M Estimate
Eldorado Gold (NYSE:EGO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.08 by 150 percent. This is a 118.18 percent decrease over earnings of $0.22 per share from the
Why Organovo Stock Is Up Today
Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).